Journal
VIROLOGY
Volume 446, Issue 1-2, Pages 268-275Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.virol.2013.08.002
Keywords
HIV-1; Gene-modified T cells; Designer T cells; Cytotoxicity; CD4-CD28-CD3 zeta; Chimeric antigen receptor; Reactivation of latent HIV
Categories
Funding
- NIH [5R21AI076145]
- Roger Williams Medical Center, Providence, RI
Ask authors/readers for more resources
The current antiretroviral therapy (ART) can effectively reduce plasma HIV loads to undetectable levels, but cannot eliminate latently infected resting memory CD4 T cells that persist for the lifetime of infected patients. Therefore, designing new therapeutic approaches to eliminate these latently infected cells or the cells that produce HIV upon reactivation from latency is a priority in the ART era in order to progress to a cure of HIV. Here, we show that designer T cells expressing chimeric antigen receptor (CAR), CD4-CD28-CD3 zeta, can target and kill HIV Env-expressing cells. Further, they secrete effector cytokines upon contact with HIV Env+ target cells that can reactivate latent HIV in a cell line model, thereby exposing those cells to recognition and killing by anti-HIV CAR+ T cells. Taken to the limit, this process could form the basis for an eventual functional or sterilizing cure for HIV in patients. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available